Buscogast (Boehringer Ingelheim India Pvt Ltd) is an Allopathic medicine for getting relief from abdominal cramping, pain and discomfort. Buscogast is antispasmodic with active ingredient Hyoscine Butylbromide. This product is known as Buscopan worldwide.
Hyoscine Butylbromide
Hyoscine-N-Butylbromide is a derivative of hyoscine which is extracted from the leaves of the Duboisia tree found mainly in Australia.
Hyoscine Butylbromide causes decreased motility of the gastrointestinal tract and the urogenital tracts. It is useful in the treatment of spasms in gastrointestinal regions (gastroenteritis, colitis, inflammatory bowel disease, biliary colic, cystitis, ureteric colic, and primary dysmenorrhea).
Some of the side effects of Hyoscine Butylbromide include Blurred vision, photophobia, increased intraocular pressure (Ocular), Dry nose, occasional bronchospasm (Respiratory), tachycardia, palpitations (Cardiovascular), Constipation, xerostomia (dry mouth), dry throat (Gastrointestinal) and Urinary retention (Renal).
Indications
Buscogast is indicated in management of non-specific colicky abdominal pain (in adults and children), irritable bowel syndrome, labour and delivery, and painful menstruation.
Dosage
Buscogast is available in form of Tablets. The recommended dose for adults and children over 6 years of age is two tablets four times a day taken about every 4-6 hours. The tablet should be swallowed whole with a glass of water.
Caution
Do not take this medicine if you are allergic to hyoscine butylbromide or to any of the other ingredients.
Do not take this medicine in case of myasthenia gravis (a condition in which the muscles become weak and tire easily), glaucoma (high pressure in the eye), porphyria (a rare blood pigment disorder), megacolon (a condition of the colon, tachyarrhythmia (a fast heart rate), achalasia (a condition that causes difficulty in swallowing food), prostatic hypertrophy (prostate problems).
Some of the symptoms of an allergic reaction due to medicine may include shortness of breath, wheezing or difficulty breathing, swelling of the face, lips, tongue or other parts of the body.
Safety and effectiveness in children younger than 6 years have not been established.